Glycaemic control and prevalence of hypoglycaemic events in children and adolescents with type 1 diabetes mellitus treated with insulin analogues

  • Ljiljana Plavšić Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
  • Katarina Mitrović Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
  • Sladjana Todorović Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
  • Rade Vuković Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
  • Tatjana Milenković Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia
  • Dragan Zdravković Mother and Child Health Care Institute of Serbia “Dr Vukan Čupić”, Belgrade, Serbia; Faculty of Medicine, University in Belgrade, Belgrade, Serbia
DOI: https://doi.org/10.2298/3802
Keywords: diabetes melitus, type 1, child, adolescent, hypoglycemia, insulin, treatment outcome,

Abstract


Background/Aim. An ideal insulin regimen for children and adolescents with type 1 diabetes mellitus (T1DM) should be physiological, flexibile and predictable, protecting against hypoglycaemia. The aim of this study was to evaluate the influence of insulin analogues on glycaemic control and the occurance of hypoglycaemic episodes in children and adolescents with T1DM. Methods. The study group consisted of 151 children and adolescents (90 boys, 61 girls) treated with human insulins for at least 12 months before introducing insulin analogues. All the patients were divided into two groups: the group I consisted of 72 (47.7%) patients treated with three injections of regular human insulin before meals and long-acting analogue (RHI/LA), and the group II of 79 (52.3%) patients treated with a combination of rapid-acting and long-acting analogue (RA/LA). The levels of glycated hemoglobin (HbA1c) and the number of hypoglycaemic episodes were assessed at the beginning of therapy with insulin analogues, and after 6 and 12 months. Results. The mean HbA1c was significantly lower in the group I (RHI/LA) after 6 months (9.15% vs 8.20%, p < 0.001) and after 12 months (9.15% vs 8.13%, p < 0.001) as well as in the group II (RA/LA) after 6 months (9.40% vs 8.24%, p < 0.001) and after 12 months of insulin analogues treatment (9.40% vs 8.38%, p < 0.001). The frequency of severe hypoglycaemia was significantly lower in both groups after 6 months (in the group I from 61.1% to 4.2% and in the group II from 54.4% to 1.3%, p < 0.001), and after 12 months (in the group I from 61.1% to 1.4% and in the group II from 54.4% to 1.3%, p < 0.001). Conclusion. Significantly better HbA1c values and lower risk of severe hypoglycaemia were established in children and adolescents with T1DM treated with insulin analogues.

References

Ludvigsson J, Bolli GB. Intensive insulin treatment in diabetic children. Diabetes Nutr Metab 2001; 14(5): 292−304.

Robertson KJ, Schoenle E, Gucev Z, Mordhorst L, Gall MA, Ludvigs-son J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 2007; 24(1): 27−34.

The Diabetes Control and Complications Trial Research Group.Hypoglycemia in the Diabetes Control and Complica-tions Trial. Diabetes 1997; 46(2): 271−86.

Rachmiel M, Perlman K, Daneman D. Insulin analogues in children and teens with type 1 diabetes: advantages and caveats. Pediatr Clin North Am 2005; 52(6): 1651−75.

Hermansen K, Fontaine P, Kukolja KK, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) ver-sus traditional human insulins (NPH insulin and regular hu-man insulin) in basal-bolus therapy for patients with type 1 di-abetes. Diabetologia 2004; 47(4): 622−9.

Rami B, Schober E. Postprandial glycaemia after regular and li-spro insulin in children and adolescents with diabetes. Eur J Pediatr 1997; 156(11): 838−40.

Ceriello A. Postprandial hyperglycemia and diabetes complica-tions: is it time to treat. Diabetes 2005; 54(1): 1−7.

Schmid H. New options in insulin therapy. J Pediatr 2007; 83(5): 146−54.

Bartley PC, Bogoev M, Larsen J, Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 2008; 25(4): 442−9.

Home PD, Lindholm A, Riis A. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. Diabet-ic medicine 2000; 17(11): 762−70.

Vague P, Selam J, Skeie S, De LI, Elte JW, Haahr H, et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26(3): 590−6.

Thalange N, Bereket A, Larsen J, Hiort LC, Peterkova V. Insulin analogues in children with Type 1 diabetes: a 52-week rando-mized clinical trial. Diabet Med 2013; 30(2): 216−25.

Barnard K, Thomas S, Royle P, Noyles K, Waugh N. Fear of hypog-lycaemia in parents of young children with type 1 diabetes: a systematic review. BMC Pediatr 2010; 10: 50.

Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia 2002; 45(7): 937−48.

Gonder-Frederick LA, Zrebiec JF, Bauchowitz AU, Ritterband LM, Magee JC, Cox DJ, et al. Cognitive function is disrupted by both hypo- and hyperglycemia in school-aged children with type 1 diabetes: a field study. Diabetes Care 2009; 32(6): 1001−6.

Hershey T, Lillie R, Sadler M, White NH. A prospective study of severe hypoglycemia and long-term spatial memory in children with type 1 diabetes. Pediatr Diabetes 2004; 5(2): 63−71.

Tupola S, Komulainen J, Jaaskelainen J, Sipila I. Post-prandial in-sulin lispro vs human regular insulin in prepubertal children with type 1 diabetes mellitus. Diabet Med 2001; 18: 654−8.

Schober E, Schoenle E, Van DJ, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15(4): 369−76.

Chase PH, Dixon B, Pearson J, Fiallo-Scharer R, Walravens P, Klin-gensmith G, et al. Reduced hypoglycemic episodes and im-proved glycemic control in children with type 1 diabetes using insulin glargine and neutral protamine Hagedorn insulin. J Pe-diatr 2003; 143(6): 737−40.

Published
2015/04/24
Issue
Vol. 71 No. 9 (2014)
Section
Original Paper